Group items tagged

The American Society for Radiation Oncology is accepting applications for its 2019 Minority Summer Fellowship Award. The annual program is designed to introduce medical students from backgrounds that are underrepresented in medicine to the discipline of radiation oncology early in their medical education. Although medical students in all years are encouraged to apply, preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will expose medical students to clinical, basic, and translational research questions in radiation oncology. The fellowship provides each student with a $4,500 package that includes a $3,500 stipend for the eight-week training program (exceptions can be made for a longer program but will need to be approved by ASTRO's Committee on Health Equity, Diversity and Inclusion, or "CHEDI") and $1,000 toward the cost of travel to the organization's 2019 annual meeting. To be eligible, applicants must be enrolled in a United States medical school and be able to identify a mentor with a successful record of research productivity. The mentor should be an ASTRO member. In addition, research must be undertaken at a North American institution during the summer of 2019.

The Fiscal Year 2015 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP): Alcohol and Substance Abuse Research Program - $4.0 million Amyotrophic Lateral Sclerosis Research Program - $7.5 million Autism Research Program - $6.0 million Bone Marrow Failure Research Program - $3.2 million Breast Cancer Research Program - $120.0 million Duchenne Muscular Dystrophy Research Program - $3.2 million Epilepsy Research Program - $7.5 million Gulf War Illness Research Program - $20.0 million Joint Warfighter Medical Research Program - $50.0 million Lung Cancer Research Program - $10.5 million Military Burn Research Program - $8.0 million Multiple Sclerosis Research Program - $5.0 million Neurofibromatosis Research Program - $15.0 million Neurotoxin Exposure Treatment Parkinson's Research Program - $16.0 million Orthotics and Prosthetics Outcomes - $10.0 million Ovarian Cancer Research Program - $20.0 million Peer Reviewed Alzheimer's Research Program - $12.0 million Peer Reviewed Cancer Research Program - $50.0 million Peer Reviewed Medical Research Program - $247.5 million Peer Reviewed Orthopaedic Research Program - $30.0 million Prostate Cancer Research Program - $80.0 million Spinal Cord Injury Research Program - $30.0 million Tuberous Sclerosis Complex Research Program - $6.0 million Vision Research Program - $10.0 million

The American Society of Breast Surgeons Foundation awards grants related to patient breast care and medical education. The foundation is a charitable organization dedicated to improving the standard of care for breast disease patients by providing support for medical and patient education, advancing breast disease research and diagnosis and treatment technologies, and offering programs and services to medical professionals and their patients.

The “Partner Actions to Improve Oral Health” program is a five-year competitive renewal to continue CDC investment in and support of oral health promotion and disease prevention programs. The purpose is to build the strength and effectiveness of state oral health programs recipients to prevent and control oral diseases and related conditions. Under component 1, recipient will work with all NOFO DP18-1810 funded programs to provide technical assistance, training, and capacity building resources for: 1) the Basic Screening Survey, 2) evidence-based oral health strategies (i.e., school sealant programs and community water fluoridation) and infection prevention and control practices, 3) oral health surveillance, 4) evaluation of oral health programs, and 5) reports on the oral health program capacity for all 50 states (CDC-funded and non-funded states). Under component 2, recipient will work with six programs selected NOFO DP18-1810 to integrate oral health with other chronic disease programs (i.e., medical/dental integration). Recipient will provide technical assistance for medical/dental integration programs, and compile examples of effective medical/dental integration programs and strategies. The proposed program will replace and build upon FOA 13-1313 [FY2013-FY2018]. Successful implementation and execution of the NOFO strategies will result in decreases in dental caries, oral health disparities, and co-morbid chronic diseases.

Founded in 2009 by two sisters from Brooklyn, the Tell Every Amazing Lady (T.E.A.L.) About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation works to drive medical research, provide survivor support, and promote public awareness and education of the signs, symptoms, and risk factors of ovarian cancer. To that end, the foundation is accepting applications for its 2019 Medical Research Program. Through the program, grants of up to $40,000 will be awarded to investigators working to advance research on ovarian cancer. To be eligible, applicants must be affiliated with a nonprofit institution in the United States.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

The Summer Undergraduate Research Fellowship (SURF) Program at Cincinnati Children's Hospital Medical Center offers undergraduates the chance to explore clinical and basic science research in laboratories in the Department of Pediatrics, University of Cincinnati College of Medicine. The primary goal is to provide students with a foundation for making career choices in the biomedical sciences. Students have the opportunity to work with one of more than 700 faculty members at Cincinnati Children's Hospital Medical Center, many of whom have active research programs that cover all areas of pediatric medicine, including the study of developmental biology, congenital disorders, genetic diseases, cancer, cardiology, neurology and immunology.

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra

Established in 2005, the Bladder Cancer Advocacy Network is a national community dedicated to increasing public understanding of bladder cancer. To that end, the network provides patients, caregivers, and the medical community with the educational resources and support services they need to navigate their bladder cancer journey and works collaboratively with the medical community to provide funding for research on effective treatments. The organization currently is accepting applications for its Young Investigator Awards program. Through the program, one-year grants of $50,000 will be awarded to two scientists working in any field that lends itself to bladder cancer research, including basic, translational, clinical, epidemiologic, or bioengineering.

The world needs more effective, functional and affordable technology solutions to clinical medical problems. With the BMEidea competition, the nation's leading competition for biomedical and bioengineering students, we challenge students to pioneer a health-related technology that addresses a real clinical need. Competition entries are judged on: Technical, economic and regulatory feasibility Contribution to human health and quality of life Technological innovation Potential for commercialization Strong BMEidea submissions define a problem and demonstrate the development of a device, product, or technology designed to solve it. BMEidea awards are presented each year at the MD&M East Medical Device Trade Show and Convention. Competition winners will receive cash awards as well as access to resources to be used for further development and commercialization of their products. In addition, the first place institution will get to display the BMEidea trophy in their winning department for the year.

Since its founding in 1979, the Skin Cancer Foundation has set the standard for educating the public and the medical community about skin cancer. The foundation is committed to reducing the incidence and mortality of the world's most common cancer, which is now occurring at epidemic levels. As part of this mission, the foundation is accepting proposals for its 2019 Research Grants Awards program. Two grants of $50,000 and one grant of $25,000 will be awarded to support one-year pilot research projects related to the disease. Researchers are invited to submit applications for projects to be conducted within the dermatology departments of medical institutions in the United States and Canada. The program is open to dermatology residents, fellows, and junior investigators.

The Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian Cancer Foundation, also known as T.E.A.L.®, is accepting applications for its 2018 Medical Research Program. The program, which aids in the advancement of ovarian cancer treatment research and the need for a screening test, offers funding in support of ovarian cancer research studies that are deemed to be most aligned with T.E.A.L.®'s mission by the organization's board of directors and a scientific advisory board. This year, the program has special interest in research related to the p53 gene, although it will accept proposals for other research related to ovarian cancer. In 2018, T.E.A.L.® will award one-year grants of up to $50,000. Project costs must be thoroughly outlined in the budget portion of the application, and grants cannot be applied to indirect costs or PI salary. All applicants must be affiliated with a non-for-profit institution in the United States and must complete all sections of the online application found here: https://goo.gl/forms/Bvk0RrwpnnQbYIjC3. (Applications from for profit organizations or federal or state government agencies will not be considered.) The deadline to submit proposals is May 31, 2018.

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

Applications to the Fiscal Year 2017 (FY17) Peer Reviewed Cancer Research Program (PRCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRCRP was initiated in 2009 to provide support for research of exceptional scientific merit and is managed by the CDMRP. Appropriations for the PRCRP from FY09 through FY16 totaled $199.8 million (M). The FY17 appropriation is $60M.

ENTELLIGENCE, in partnership with Actelion Pharmaceuticals US, supports basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension. To that end, ENTELLIGENCE is accepting applications for its thirteenth annual Young Investigator grant program. Established in 2005, the program provides opportunities for promising young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension specifically related to expanding knowledge of pulmonary vascular pathobiology pathways. In 2018, the program will award a one-year grant of up to $100,000 to fund a mentored project.

The Medical Research Fellows Program enables students to be immersed in a high-impact, intensive research experience at a critical time in their professional education, before they make plans for residency or postdoctoral training. Unique aspects of the program include national and regional professional development activities, mentorship by physician-scientists, interaction with HHMI investigators, and integration into a community of like-minded peers. Each student selects and works with a mentor to develop a basic, translational, or applied biomedical research proposal. Both mentor selection and the research proposal are key components of the fellowship application; working with an HHMI scientist is encouraged but not required. Mentors can be at any academic or nonprofit research institution in the United States (excluding the National Institutes of Health and any other government agency) or at HHMI's Janelia Research Campus in Ashburn, VA. 

The Leukemia & Lymphoma Society has issued new Requests for Proposals through its Translational Research Program to support researchers in six critical areas of unmet medical need. The RFPs mark LLS's aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. The LLS Translational Research Program is designed to help accelerate the movement of promising discoveries from lab to clinic. The goal of translational research is to reduce the time between laboratory findings and actual treatment. The society aims to stimulate more academic research in the following areas: new immunotherapeutics for patients with acute myelogenous leukemia; novel therapeutics for patients with non-cutaneous T-cell malignancies; introduction of novel agents in the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma; therapies for patients with myelodysplastic syndromes who have failed hypomethylating agents; therapies for new targets such as bromodomains, methylation, and other epigenetic approaches for patients with high-risk myeloma; and research that addresses long-term and late effects of blood cancer therapies.